National Biotechnology Safety Act

# National Biotechnology Safety Act Summary **What the Bill Would Do** The National Biotechnology Safety Act (S 2697) would establish federal safety and oversight standards for biotechnology research and development. While the bill's specific provisions aren't detailed in the available information, biotechnology safety bills typically aim to create clear rules for how scientists and companies can work with genetic engineering, synthetic biology, and other advanced biological technologies. The goal would be to ensure these powerful tools are developed and used safely while protecting public health and the environment. **Who It Affects** This legislation would primarily affect biotechnology companies, research institutions, universities, and government laboratories that conduct genetic engineering or similar biological research. It could also impact regulatory agencies like the FDA and EPA, which would likely play a role in enforcing the new standards.

Ultimately, the bill's safety framework could affect the general public by influencing how new biotech products—such as genetically modified foods, gene therapies, or industrial biologics—are developed and brought to market. **Current Status** As of now, S 2697 remains in committee, meaning it hasn't yet been debated or voted on by the full Senate. The bill was introduced by Senator Todd Young (R-IN) in the 119th Congress. For more specific details about the bill's exact provisions, consulting Congress.gov or the bill's official text would provide comprehensive information.